ADVANCED CLINICAL TRIAL SUITE
for Psychedelic Therapeutics & Behavioral Health Research

“ Expanding the frontiers of mental health - one trial at a time.”

CATEGORY

Psychedelic Medicine • Neuropsychiatry • Addiction Research • Palliative & Behavioral Health

PERATIONAL RELEVANCE

Innovative behavioral health and psychedelic-assisted interventions are rapidly gaining traction as tools to address military mental health challenges, including PTSD, treatment-resistant depression, and substance use disorders. LSU Health Shreveport’s integrated psychedelic research and clinical trials environment offers an operationally relevant platform for DoD, VA, and NIH collaborations with high-need behavioral health cohorts.

The program is supported by a team of board-certified psychiatrists, neuropsychologists, clinical trial coordinators, scientific researchers and regulatory staff experienced in IND/IDE research. Partnerships with radiochemistry and imaging experts at the Center for Molecular Imaging and Therapy (CMIT) further enhance translational trial support.

The Clinical Trial Suite includes 10 patient rooms, a group therapy treatment area, check-in and recovery areas, and infrastructure for:

• Psychedelic Dosing
• Group-based sessions and infusion capabilities (e.g., ketamine)
• EEG, MRI, PET, and virtual reality for cognitive and emotional assessments
• Radiopharmaceutical capabilities supported by the Center for Molecular Imaging and Therapy (CMIT)
• TMS treatments and assessments
• Cardiometabolic and neurocognitive
• Access to various populations with limited access via established community partnerships

MILITARY-ALIGNED BENEFITS

• Validated infrastructure to support FDA-regulated psychedelic trials
• Ability to explore potential therapies for substance use disorders, depression, and PTSD trauma using real-world population models
• Combines neuroimaging, neurocognitive, and psychophysiological metrics
• Community and veteran partnerships enable broad participant access
• Platform for innovative mind-body and neuroplasticity studies

Hosting of Externally Sponsored or DoD-funded Psychedelic Trial Protocols

• Platform for SBIR/STTR collaboration in neuropsychiatric therapeutic validation
• Regulatory and clinical support for IND/IDE trial partners
• Treatment-resistant PTSD or depression in service members and veterans
• Substance use disorder treatment programs including methamphetamine use disorder
• Cognitive enhancement and emotional regulation for high-stress operators
• Palliative applications including terminal distress and adjustment disorders

Current & Recent Psychedelics Clinical Trials

• Psilocybin (oral): Methamphetamine-use disorder – Investigator-initiated, Ongoing
• 5-MeO-DMT (intranasal): Methamphetamine-use disorder – Sponsor-initiated, On Hold
• 5-OH-DiPT (subcutaneous): Postpartum depression – Sponsor-initiated, Complete
• 5-OH-DiPT (subcutaneous): Adjustment disorder – Sponsor-initiated, Not started
• N,N-DMT (buccal): Treatment-resistant depression – Sponsor-initiated, Not started